Abbott-Epic Tie-Up Brings Real-Time CGM Data to EHRs

The integration streamlines access to glucose data in patient charts, saving time and increasing time for informed care management and decision-making.

Abbott, a global healthcare leader, has joined hands with US-based healthcare software developer Epic Systems to integrate patient glucose data from its FreeStyle Libre CGM systems directly into Epic’s EHR platform.

The move aims to enhance workflow efficiency for healthcare providers and improve diabetes management for the Americans.

Alan Hutchison, vice president at Epic, said, “Our work with Abbott aims to make life simpler for the nearly 40 million people in the US who live with diabetes today. This will help everyone focus more on patient care and less on administrative hurdles.”

How Will it Work?

The integration leverages Epic’s Aura software, a platform designed to connect health systems with diagnostics labs and medical device manufacturers.

Through this new capability, glucose data from a patient’s LibreView account will be automatically linked to their electronic chart within Epic.

Reportedly, after this clinicians will be able to access patients’ glucose readings and trends seamlessly before, during, and after consultations without leaving their preferred workflow.

Over 575,000 US healthcare providers, serving approximately 280 million patients, use Epic’s systems.

With this integration, these providers will now have streamlined access to critical glucose data directly within their patients’ charts.

This is expected to reduce time spent searching for data and increase time available for informed care management and decision-making.

For patients using FreeStyle Libre systems, the integration facilitates easier collaboration with healthcare teams.

The access to CGM data is anticipated to foster better understanding of glucose patterns and encourage positive behavior changes in diabetes self-management.

Moreover, the connection facilitates a more integrated approach to diabetes care between patients and their healthcare providers.

Last year Abbott launched the AVEIR VR leadless pacemaker, , a minimally invasive device designed for patients with slow heart rhythms, and is also advancing chronic disease care through seven biosimilars in areas like cancer and cardiovascular health.

Alongside product innovation, Abbott is strengthening digital healthcare delivery with connected care solutions, and its Mumbai centers are driving global innovation in diabetes care, pharmaceuticals, and data analytics.

Stay tuned for more such updates on Digital Health News.